ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse
- PMID:11082453
ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse
Abstract
Adenosine (ADO) is an inhibitory neuromodulator that can increase nociceptive thresholds in response to noxious stimulation. Inhibition of the ADO-metabolizing enzyme adenosine kinase (AK) increases extracellular ADO concentrations at sites of tissue trauma and AK inhibitors may have therapeutic potential as analgesic and anti-inflammatory agents. ABT-702 is a novel and potent (IC(50) = 1. 7 nM) non-nucleoside AK inhibitor that has several orders of magnitude selectivity over other sites of ADO interaction (A(1), A(2A), A(3) receptors, ADO transporter, and ADO deaminase). ABT-702 was 1300- to 7700-fold selective for AK compared with a number of other neurotransmitter and peptide receptors, ion channel proteins, neurotransmitter/nucleoside reuptake sites, and enzymes, including cycloxygenases-1 and -2. ABT-702 was equipotent (IC(50) = 1.5 +/- 0. 3 nM) in inhibiting native human AK (placenta), two human recombinant isoforms (AK(long) and AK(short)), and AK from monkey, dog, rat, and mouse brain. Kinetic studies revealed that AK inhibition by ABT-702 was competitive with respect to ADO and noncompetitive with respect to MgATP(2-). AK inhibition by ABT-702 was demonstrated to be reversible after 4 h of dialysis. ABT-702 is orally active and fully efficacious in reducing acute somatic nociception (ED(50) = 8 micromol/kg i.p.; 65 micromol/kg p.o.) in the mouse hot-plate assay. ABT-702 also dose dependently reduced nociception in the phenyl-p-quinone-induced abdominal constriction assay. The antinociceptive effects of ABT-702 in the hot-plate assay were blocked by the nonselective ADO receptor antagonist theophylline, and by the A(1)-selective antagonist cyclopentyltheophylline (10 mg/kg i.p.), but not by a peripherally selective ADO receptor antagonist 8-(p-sulfophenyl)-theophylline (50 mg/kg i.p.), by the A(2A)-selective antagonist 3, 7-dimethyl-1-propargylxanthine (1 mg/kg i.p.) or the opioid antagonist naloxone (5 mg/kg i.p.). Thus, ABT-702 is a novel and potent non-nucleoside AK inhibitor that effectively reduces acute thermal nociception in the mouse by a nonopioid, non-nonsteroidal anti-inflammatory drug, ADO A(1) receptor-mediated mechanism.
Similar articles
- Recent developments in the discovery of novel adenosine kinase inhibitors: mechanism of action and therapeutic potential.McGaraughty S, Cowart M, Jarvis MF.McGaraughty S, et al.CNS Drug Rev. 2001 Winter;7(4):415-32. doi: 10.1111/j.1527-3458.2001.tb00208.x.CNS Drug Rev. 2001.PMID:11830758Free PMC article.Review.
- ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat.Kowaluk EA, Mikusa J, Wismer CT, Zhu CZ, Schweitzer E, Lynch JJ, Lee CH, Jiang M, Bhagwat SS, Gomtsyan A, McKie J, Cox BF, Polakowski J, Reinhart G, Williams M, Jarvis MF.Kowaluk EA, et al.J Pharmacol Exp Ther. 2000 Dec;295(3):1165-74.J Pharmacol Exp Ther. 2000.PMID:11082454
- The adenosine kinase inhibitor ABT-702 augments EEG slow waves in rats.Radek RJ, Decker MW, Jarvis MF.Radek RJ, et al.Brain Res. 2004 Nov 5;1026(1):74-83. doi: 10.1016/j.brainres.2004.08.011.Brain Res. 2004.PMID:15476699
- Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis.Boyle DL, Kowaluk EA, Jarvis MF, Lee CH, Bhagwat SS, Williams M, Firestein GS.Boyle DL, et al.J Pharmacol Exp Ther. 2001 Feb;296(2):495-500.J Pharmacol Exp Ther. 2001.PMID:11160636
- Adenosine kinase inhibitors.Kowaluk EA, Bhagwat SS, Jarvis MF.Kowaluk EA, et al.Curr Pharm Des. 1998 Oct;4(5):403-16.Curr Pharm Des. 1998.PMID:10197052Review.
Cited by
- Nucleoside transporter subtype expression: effects on potency of adenosine kinase inhibitors.Sinclair CJ, Powell AE, Xiong W, LaRivière CG, Baldwin SA, Cass CE, Young JD, Parkinson FE.Sinclair CJ, et al.Br J Pharmacol. 2001 Nov;134(5):1037-44. doi: 10.1038/sj.bjp.0704349.Br J Pharmacol. 2001.PMID:11682452Free PMC article.
- Recent developments in the discovery of novel adenosine kinase inhibitors: mechanism of action and therapeutic potential.McGaraughty S, Cowart M, Jarvis MF.McGaraughty S, et al.CNS Drug Rev. 2001 Winter;7(4):415-32. doi: 10.1111/j.1527-3458.2001.tb00208.x.CNS Drug Rev. 2001.PMID:11830758Free PMC article.Review.
- Adenosine kinase: A key regulator of purinergic physiology.Boison D, Jarvis MF.Boison D, et al.Biochem Pharmacol. 2021 May;187:114321. doi: 10.1016/j.bcp.2020.114321. Epub 2020 Nov 6.Biochem Pharmacol. 2021.PMID:33161022Free PMC article.Review.
- Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury.Módis K, Gerő D, Stangl R, Rosero O, Szijártó A, Lotz G, Mohácsik P, Szoleczky P, Coletta C, Szabó C.Módis K, et al.Int J Mol Med. 2013 Feb;31(2):437-46. doi: 10.3892/ijmm.2012.1203. Epub 2012 Dec 4.Int J Mol Med. 2013.PMID:23232950Free PMC article.
- An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1.Aftab F, Rodriguez-Fuguet A, Silva L, Kobayashi IS, Sun J, Politi K, Levantini E, Zhang W, Kobayashi SS, Zhang WC.Aftab F, et al.Br J Cancer. 2023 May;128(9):1647-1664. doi: 10.1038/s41416-023-02196-z. Epub 2023 Feb 21.Br J Cancer. 2023.PMID:36810913Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Other Literature Sources
Chemical Information
Medical
Molecular Biology Databases